Market Cap ₹30075 Cr.
Stock P/E 38.9
P/B 3.4
Current Price ₹1825.5
Book Value ₹ 533.4
Face Value 1
52W High ₹2221
Dividend Yield 1.1%
52W Low ₹ 1590
Gland Pharma Ltd engages in the development, manufacture, and marketing of injectable-focused widespread liquid parental merchandise. The agency's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its merchandise below diverse therapeutic categories, which include anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, ache management, hormones and associated tablets, fertility dietary supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, breathing, blood related, ophthalmological and otological, ache/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The business enterprise additionally affords contract improvement services. It sells its products mainly under a business to business in the United States, Europe, Canada, Australia, India, and across the world. The enterprise incorporated in 1978 and is based in Hyderabad, India.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 857 | 1044 | 938 | 785 | 1209 | 1373 | 1545 | 1537 | 1402 | 1406 |
| Other Income | 74 | 66 | 62 | 39 | 38 | 53 | 37 | 42 | 51 | 60 |
| Total Income | 931 | 1110 | 1000 | 824 | 1246 | 1427 | 1583 | 1580 | 1453 | 1465 |
| Total Expenditure | 587 | 748 | 649 | 617 | 915 | 1049 | 1189 | 1179 | 1137 | 1109 |
| Operating Profit | 344 | 362 | 351 | 207 | 331 | 377 | 394 | 401 | 316 | 357 |
| Interest | 1 | 2 | 3 | 2 | 5 | 6 | 5 | 10 | 6 | 6 |
| Depreciation | 35 | 37 | 38 | 38 | 65 | 81 | 105 | 93 | 92 | 94 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -56 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 308 | 324 | 311 | 111 | 261 | 290 | 283 | 298 | 218 | 257 |
| Provision for Tax | 79 | 83 | 79 | 32 | 67 | 96 | 91 | 106 | 74 | 93 |
| Profit After Tax | 229 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 229 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 |
| Adjusted Earnings Per Share | 13.9 | 14.6 | 14.1 | 4.8 | 11.8 | 11.8 | 11.6 | 11.7 | 8.7 | 9.9 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 2633 | 3463 | 4401 | 3625 | 5665 | 5890 |
| Other Income | 139 | 135 | 224 | 240 | 170 | 190 |
| Total Income | 2772 | 3598 | 4625 | 3865 | 5835 | 6081 |
| Total Expenditure | 1678 | 2161 | 2891 | 2600 | 4332 | 4614 |
| Operating Profit | 1095 | 1437 | 1734 | 1265 | 1503 | 1468 |
| Interest | 7 | 3 | 5 | 7 | 26 | 27 |
| Depreciation | 95 | 99 | 110 | 147 | 345 | 384 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -56 | 0 | 0 |
| Profit Before Tax | 993 | 1335 | 1619 | 1055 | 1133 | 1056 |
| Provision for Tax | 220 | 338 | 407 | 274 | 360 | 364 |
| Profit After Tax | 773 | 997 | 1212 | 781 | 772 | 692 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 773 | 997 | 1212 | 781 | 772 | 692 |
| Adjusted Earnings Per Share | 49.9 | 60.9 | 73.7 | 47.4 | 46.9 | 41.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 56% | 18% | 0% | 0% |
| Operating Profit CAGR | 19% | 2% | 0% | 0% |
| PAT CAGR | -1% | -8% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -3% | -22% | NA% | NA% |
| ROE Average | 9% | 13% | 16% | 16% |
| ROCE Average | 14% | 18% | 22% | 22% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Shareholder's Funds | 3646 | 5903 | 7158 | 7959 | 8724 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 4 | 4 | 4 | 3 | 107 |
| Other Non-Current Liabilities | 77 | 76 | 90 | 86 | 382 |
| Total Current Liabilities | 359 | 513 | 582 | 729 | 1398 |
| Total Liabilities | 4086 | 6496 | 7834 | 8778 | 10611 |
| Fixed Assets | 968 | 954 | 1502 | 1571 | 3947 |
| Other Non-Current Assets | 272 | 418 | 479 | 306 | 1019 |
| Total Current Assets | 2846 | 5124 | 5852 | 6901 | 5645 |
| Total Assets | 4086 | 6496 | 7834 | 8778 | 10611 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 236 | 169 | 492 | 319 | 1909 |
| Cash Flow from Operating Activities | 701 | 605 | 791 | 364 | 997 |
| Cash Flow from Investing Activities | -766 | -1524 | -1003 | 1208 | -1757 |
| Cash Flow from Financing Activities | -7 | 1238 | 35 | 15 | -799 |
| Net Cash Inflow / Outflow | -72 | 319 | -177 | 1587 | -1560 |
| Closing Cash & Cash Equivalent | 169 | 492 | 319 | 1909 | 357 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 49.88 | 60.94 | 73.75 | 47.42 | 46.9 |
| CEPS(Rs) | 55.98 | 66.98 | 80.46 | 56.33 | 67.82 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 20 |
| Book NAV/Share(Rs) | 234.25 | 359.3 | 434.84 | 483.12 | 529.56 |
| Core EBITDA Margin(%) | 36.28 | 37.61 | 34.32 | 28.27 | 23.53 |
| EBIT Margin(%) | 37.98 | 38.64 | 36.9 | 29.3 | 20.46 |
| Pre Tax Margin(%) | 37.71 | 38.55 | 36.78 | 29.1 | 19.99 |
| PAT Margin (%) | 29.35 | 28.79 | 27.53 | 21.55 | 13.64 |
| Cash Profit Margin (%) | 32.94 | 31.64 | 30.04 | 25.6 | 19.72 |
| ROA(%) | 18.91 | 18.84 | 16.91 | 9.4 | 7.97 |
| ROE(%) | 21.29 | 20.97 | 18.61 | 10.34 | 9.26 |
| ROCE(%) | 27.39 | 28 | 24.85 | 14.04 | 13.63 |
| Receivable days | 83.41 | 67.08 | 72.4 | 97.99 | 78.29 |
| Inventory Days | 104.83 | 107.06 | 102.05 | 157.65 | 116 |
| Payable days | 108.75 | 96.63 | 74.34 | 113.72 | 121.78 |
| PER(x) | 0 | 40.66 | 44.33 | 26.75 | 39.27 |
| Price/Book(x) | 0 | 6.9 | 7.52 | 2.63 | 3.48 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 1.09 |
| EV/Net Sales(x) | -0.5 | 10.84 | 11.5 | 4.73 | 5.09 |
| EV/Core EBITDA(x) | -1.19 | 26.12 | 29.19 | 13.54 | 19.17 |
| Net Sales Growth(%) | 0 | 31.51 | 27.08 | -17.64 | 56.29 |
| EBIT Growth(%) | 0 | 33.82 | 21.34 | -34.6 | 9.11 |
| PAT Growth(%) | 0 | 29 | 21.54 | -35.54 | -1.1 |
| EPS Growth(%) | 0 | 22.18 | 21.01 | -35.7 | -1.11 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0.04 |
| Current Ratio(x) | 7.93 | 10 | 10.05 | 9.46 | 4.04 |
| Quick Ratio(x) | 5.82 | 7.51 | 8.02 | 6.8 | 2.85 |
| Interest Cover(x) | 139.24 | 392.33 | 309.77 | 142.61 | 44.23 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.01 |
| # | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 57.87 | 57.86 | 57.86 | 57.86 | 57.86 | 57.86 | 57.86 | 57.86 | 51.83 | 51.83 |
| FII | 9.41 | 6.09 | 4.66 | 4.32 | 2.8 | 4.91 | 4.04 | 3.59 | 6.88 | 4.47 |
| DII | 17.37 | 21.91 | 23.13 | 23.24 | 23.38 | 22.45 | 24.17 | 25.23 | 32.83 | 35.37 |
| Public | 15.35 | 14.13 | 14.34 | 14.58 | 15.96 | 14.78 | 13.93 | 13.32 | 8.45 | 8.32 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 9.53 | 9.53 | 9.53 | 9.53 | 9.53 | 9.53 | 9.53 | 9.53 | 8.54 | 8.54 |
| FII | 1.55 | 1 | 0.77 | 0.71 | 0.46 | 0.81 | 0.67 | 0.59 | 1.13 | 0.74 |
| DII | 2.86 | 3.61 | 3.81 | 3.83 | 3.85 | 3.7 | 3.98 | 4.16 | 5.41 | 5.83 |
| Public | 2.53 | 2.33 | 2.36 | 2.4 | 2.63 | 2.44 | 2.29 | 2.19 | 1.39 | 1.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16.47 | 16.47 | 16.47 | 16.47 | 16.47 | 16.47 | 16.47 | 16.47 | 16.48 | 16.48 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
